`` Plasma '' recovered from new type coronavirus infection is regarded as a promising therapeutic drug

The pandemic of the new coronavirus infection (COVID-19) is widespread

, with more than 42,000 deaths worldwide as of March 31, 2020. As a treatment for such COVID-19, a person who has recovered from a new type of coronavirus infection plasma ( Let's go ) Is attracting attention.

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma | Critical Care Medicine | JAMA | JAMA Network

Coronavirus survivors' blood plasma could be used to fight infection | Science | The Guardian

The human body can produce 'antibodies' from the immune system to get rid of the virus. The plasma of a person who recovers from the disease is called 'recovery plasma' because it contains many antibodies. Treatment using convalescent plasma has been known for a long time, and treatment with convalescent plasma has been attempted for the Spanish cold and Ebola hemorrhagic fever, which were prevalent in 1918.

At the time of writing, no cure for COVID-19 exists, but some have cured COVID-19. A team from the National Vaccine Research Institute in China said on March 27, 2020, `` Recovery in five severe patients with acute respiratory distress syndrome (ARDS) who have severe respiratory failure due to new coronavirus infection Administration of anaphase plasma improved his condition. '

All five critically ill patients required respirators, but within 3 days of administration, 4 of 5 had normal temperature and within 12 days had a negative viral response That In addition, three had no ventilator within two weeks of administration and were discharged 51-55 days after admission. The remaining two patients remain hospitalized, but their condition has stabilized 37 days after administration.

A research team at the University of Glasgow in the United Kingdom has focused on those who have recovered from COVID-19 and who have a constitution called 'Hyperimmune', which has more antibodies than ordinary people. Filed with the National Institutes of Health for permission to conduct a clinical trial using Hyperimmune human convalescent plasma as a therapeutic. 'We could work like a vaccine to prevent COVID-19, but we don't think it will work in critically ill patients who need a ventilator,' said David Tappin, a research team professor. In any case, without a trial, we can't tell if this treatment is effective. '

`` We are planning to conduct parallel testing of convalescent plasma, '' said Professor Robert Lechler, chairman of the British Academy of Medicine and permanent director of King's Health Partners , which operates three hospitals in London. Commented on the Guardian. 'We have already begun work on identifying potential donors for convalescent plasma,' said a spokesman for the National Blood Service in the UK.

A similar initiative is underway in the United States, with New York State governor Andrew Cuomo announcing a trial of convalescent plasma therapy on March 20, 2020.

A clinical trial of a treatment method using `` blood of a person who has recovered from a new type coronavirus infection '' will be carried out in New York-gigazine

in Science, Posted by darkhorse_log